Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

Basit Öğe Kaydı
dc.authoridDEMIRCI, UMUT/0000-0002-4833-6721
dc.authoridDursun, Oldac Uras/0000-0003-2801-9582
dc.authorwosidSendur, Mehmet Ali Nahit/H-7555-2014
dc.contributor.authorKilickap, Saadettin
dc.contributor.authorAk, Sertac
dc.contributor.authorDursun, Oldac U.
dc.contributor.authorSendur, Mehmet A. N.
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorDemirci, Umut
dc.date.accessioned2024-05-19T14:38:54Z
dc.date.available2024-05-19T14:38:54Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractThe use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor, has demonstrated significant systemic and intracranial activity in both first-line and subsequent-line therapy in ALK-positive NSCLC patients. In this review, general characteristics of lorlatinib, its efficacy in the treatment of ALK-positive NSCLC patients and the safety of lorlatinib, particularly addressing CNS adverse events, are discussed. Management of CNS adverse events, which seem to be specific to lorlatinib therapy, is outlined. Plain language summary - Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse eventsLung cancer is a common disease and affects patients badly. Lorlatinib is a new and useful drug for this disease. But this drug has also some undesirable effects for the brain. These effects are generally mild and can be treated. This article discusses the undesirable effects of this drug on the brain and how to cope with these effects.en_US
dc.identifier.doi10.2217/fon-2023-0014
dc.identifier.endpage2012en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue29en_US
dc.identifier.pmid37449387en_US
dc.identifier.scopus2-s2.0-85177049685en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage2003en_US
dc.identifier.urihttps://doi.org10.2217/fon-2023-0014
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4642
dc.identifier.volume19en_US
dc.identifier.wosWOS:001024718800001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectAdverse Drug Reactionsen_US
dc.subjectCentral Nervous Systemen_US
dc.subjectHyperlipidemiaen_US
dc.subjectLorlatiniben_US
dc.subjectLung Canceren_US
dc.titleSafety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse eventsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu